SpringWorks Therapeutics Reports First Quarter 2024
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the…
SpringWorks Therapeutics Reports First Quarter 2024
– Achieved $21.0 million in OGSIVEO® (nirogacestat) net product revenue in the…
SpringWorks Therapeutics Announces Abstracts Accepted for
– Results from Phase 2b ReNeu trial of mirdametinib in NF1-PN accepted…
SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors
SpringWorks Therapeutics, Inc.Application based on Phase 3 DeFi trial in which nirogacestat…
SpringWorks Therapeutics Announces European Medicines
STAMFORD, Conn., Feb. 29, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq:…